Publications

5803 Results

S2005: A phase II randomized study comparing ibrutinib and rituximab (IR) vs. venetoclax and rituximab (VR) in previously untreated Waldenstro¨m’s macroglobulinemia (WM) / lymphoplasmacytic lymphoma (LPL)

Authors
Sikander Ailawadhi, MD
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #1840
Year
2025
Research Committee(s)
Myeloma
Study Number(s)
S2005

A randomized Phase II trial of ASTX727 and venetoclax with or without enasidenib for newly diagnosed older adults with IDH2 mutant Acute Myeloid Leukemia: A myeloMATCH substudy (MM1OA-S03)

Authors
Eric Huselton, MD
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #3466
Year
2025
Research Committee(s)
Leukemia
Study Number(s)
MM1OA-S03

Interim and end-of-treatment FDG-PET demonstrate limited ability to predict 3-year progression-free survival with nivolumab-AVD in first-line treatment of advanced stage Hodgkin lymphoma: Imaging sub-analysis of Phase 3 S1826 study

Authors
Nancy Bartlett, MD
Journal / Conference
ASH Annual Meeting (December 6-9, 2025, Orlando, FL) #1851
Year
2025
Research Committee(s)
Lymphoma
Study Number(s)
S1826

Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE): Cluster Randomized Controlled Trial of Decision Support for Breast Cancer Chemoprevention, SWOG 1904

Authors
Katherine D. Crew
Journal / Conference
San Antonio Breast Cancer Symposium (December 9-12, 2025, San Antonio, TX)
Year
2025
Research Committee(s)
Prevention, Screening, and and Surveillance
Study Number(s)
S1904

Sentinel Lymph Node Biopsy and Clinical Outcome of Patients with Node-Positive Breast Cancer in the RxPONDER Trial (S1007)

Authors
Rosa F. Hwang
Journal / Conference
San Antonio Breast Cancer Symposium (December 9-12, 2025, San Antonio, TX)
Year
2025
Research Committee(s)
Breast
Study Number(s)
S1007

Sex differences in chemotherapy completion and adverse events among patients with colon cancer (CALGB/SWOG 80702) (Alliance)

Authors
E. Cheng
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #3624 poster
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Association between empirical dietary inflammatory pattern (EDIP) and survival in patients with stage III colon cancer: Findings from CALGB/SWOG 80702 (Alliance)

Authors
S.K. Char
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #LBA3509
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80702

Pragmatica-Lung (SWOG S2302): A prospective pragmatic randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer

Authors
K.H. Dragnev
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #LBA8671
Year
2025
Research Committee(s)
Lung
Study Number(s)
S2302

Validation and refinement of Society of Immunotherapy of Cancer (SITC) definitions for PD-(L)1 resistance: An analysis of more than 1,300 participants from SWOG

Authors
M. Othus
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #2656 poster
Year
2025
Research Committee(s)
Early Therapeutics and Rare Cancers and Melanoma
Study Number(s)
S1404, S1609

Long non-coding RNA (lncRNA) SNHG11 as a prognostic and predictive biomarker in metastatic colorectal cancer (mCRC): Insights from CALGB (Alliance)/SWOG 80405

Authors
M. Bartolini
Journal / Conference
ASCO Annual Meeting (May 30 to June 3, 2025, Chicago, Il), #3128 poster
Year
2025
Research Committee(s)
Gastrointestinal
Study Number(s)
CTSU/C80405